-
Mashup Score: 5VJHemOnc β The video journal of hematological oncology - 5 day(s) ago
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve the awareness and understanding of hematological cancers
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Claire Harrison, MD, FRCP, FRCPath, Guyβs & St Thomasβ NHS Foundation Trust, London, UK, provides a comprehensive overview of the current key trials in the United Kingdom in the field of myeloproliferative neoplasms (MPN). In essential thrombocythemia (ET), bomedemstat and calreticulin-directed therapies are being investigated. For patients with polycythemia vera (PV), hepcidin agonists are being trialed for reducing venesection requirements and iron deficiency, and the MITHRIDATE study (NCT04116502) is comparing ruxolitinib to hydroxycarbamide or interferon as frontline therapy for high-risk patients. In myelofibrosis (MF), calreticulin-targeting therapies are also being assessed, and several ongoing trials, including FEDORA (ISRCTN88102629) and PROMise (ISRCTN12451433), are investigating combination therapies. Prof. Harrison also highlights the launch of the myMPNVoice app, which will allow patients to track symptoms and facilitate the collection of a large volume of real-world data.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5VJHemOnc β The video journal of hematological oncology - 6 day(s) ago
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve the awareness and understanding of hematological cancers
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet-
#SOHO2023 is taking place next week in Houston, TX!π We @VJHemOnc are looking forward to interviewing and sharing the latest in #Leukemia, #Lymphoma and more. Follow us and check out https://t.co/O9p0vDBrzw to stay updated! @SocietyofHemOnc #LeuSM #LymSM #MMsm #MDSsm #MPNsm https://t.co/cQo18FkF3a
-
-
Mashup Score: 1Current SoC for BPDCN and other emerging treatment options - 6 day(s) ago
Cristina Papayannidis, MD, PhD, University of Bologna, Bologna, Italy, summarizes the current standard of care (SoC) for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Tagraxofusp, a first-in-class CD123-targeted agent, is particularly efficacious for first-line adult patients with BPDCN. Dr Papayannidis highlights that allogeneic stem cell transplantation (alloSCT) is utilized in virtually all cases of BPDCN following standard chemotherapy regimens. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2BSH 2024 | VJHemOnc - 7 day(s) ago
The 64th Annual Scientific Meeting of the British Society for Haematology (BSH) took place on 28-30 April 2024 in Liverpool, UK, and brought together hematology professionals to discuss advances in the field. The 64th Annual Scientific Meeting of the British Society for Haematology (BSH) took place on 28-30 April 2024 in Liverpool, UK, and brought together hematology professionals to discuss advances in the field. We use cookies to provide the best experience on our website. We also use third party
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet-
We had an amazing time at #BSH2024 and want to say a big thank you to @BritSocHaem for having us on-site!π Exclusive interviews from the meeting are already available to watch on our site, with many more to come! π₯ Watch here: π https://t.co/vVSV7VpUkv #HemOnc #Hematology https://t.co/LnT5jTyKKE
-
-
Mashup Score: 31
Sanam Loghavi and Naval Daver discuss the current approach to the diagnosis and classification, risk-stratification and treatment options for newly diagnosed AML in the context of recurrent genetic alterations.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5Using MRD to guide treatment decisions in myeloma - 7 day(s) ago
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the potential for using measurable residual disease (MRD) status to guide treatment decisions in clinical practice. Patients with multiple myeloma (MM) who achieve MRD-negativity may be able to discontinue treatment early and undergo a treatment-free interval. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
MaΓ«l Heiblig, MD, HΓ΄pital Lyon Sud, Lyon, France, discusses the current treatment approaches for patients with VEXAS syndrome, which include controlling inflammation, controlling the clone, and supportive care. Dr Heiblig hopes that prospective trials will be initiated in this patient population shortly to assess the safety and efficacy of the treatments being used, as no standard of care currently exists. This interview took place at the European School of Hematology 9th Translational Research Conference on Myelodysplastic Syndromes (ESH MDS) in Budapest, Hungary. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0FDA approves fidanacogene elaparvovec, a one-time gene therapy, for adult patients with hemophilia B - 9 day(s) ago
Read about the FDA approval of fidanacogene elaparvovec, a one-time gene therapy, for adults with hemophilia B.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Highlights from EBMT 2024: treating & managing GvHD & understanding the role of the gut microbiome - 9 day(s) ago
Tune in to this week’s VJHemOnc podcast to learn more about current & emerging treatment options for acute & chronic GvHD, as well as the role of the gut microbiome.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
#SOHO2023 is taking place next week in Houston, TX!π We @VJHemOnc are looking forward to interviewing and sharing the latest in #Leukemia, #Lymphoma and more. Follow us and check out https://t.co/O9p0vDBrzw to stay updated! @SocietyofHemOnc #LeuSM #LymSM #MMsm #MDSsm #MPNsm https://t.co/cQo18FkF3a